Acumen Pharmaceuticals, Inc.

NasdaqGS ABOS

Acumen Pharmaceuticals, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 323.19

Acumen Pharmaceuticals, Inc. Price to Sales Ratio (P/S) is 323.19 on January 14, 2025, a -56.83% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Acumen Pharmaceuticals, Inc. 52-week high Price to Sales Ratio (P/S) is 956.99 on March 01, 2024, which is 196.11% above the current Price to Sales Ratio (P/S).
Acumen Pharmaceuticals, Inc. 52-week low Price to Sales Ratio (P/S) is 323.19 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
Acumen Pharmaceuticals, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 606.42.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: ABOS

Acumen Pharmaceuticals, Inc.

CEO	Mr. Daniel J. O'Connell M.B.A.
IPO Date	July 1, 2021
Location	United States
Headquarters	427 Park Street
Employees	51
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Key trends

Past 5 years